Imovax® Rabies and VERORAB® Immunogenicity and Safety After One Week 2-sites Intradermal or 1-site Intramuscular Pre-Exposure Prophylaxis Regimens, Followed by a Simulated Post-Exposure Prophylaxis Regimen at One Year
Clinical trial NCT03700242 · COMPLETED
Trial details
- NCT number
- NCT03700242
- Sponsor
- Sanofi Pasteur, a Sanofi Company
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-09-26
- Primary completion
- 2019-01-19
- Enrollment
- 570
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.